Development and therapeutic evaluation of 5D3(CC-MLN8237)3.2 antibody-theranostic conjugates for PSMA-positive prostate cancer therapy

Prostate cancer (PC) is an aggressive cancer that can progress rapidly and eventually become castrate-resistant prostate cancer (CRPC). Stage IV metastatic castrate-resistant prostate cancer (mCRPC) is an incurable late-stage cancer type with a low 5-year overall survival rate. Targeted therapeutics...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Ioanna Liatsou, Betelhem Assefa, Wathsala Liyanage, Sharmane Surasinghe, Zora Nováková, Cyril Bařinka, Kathleen Gabrielson, Venu Raman, Dmitri Artemov, Sudath Hapuarachchige
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2024-05-01
Ráidu:	Frontiers in Pharmacology
Fáttát:	prostate cancer PSMA -prostate-specific membrane antigen image-guided drug delivery targeted therapy theranostics Aurora A kinase inhibition
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1385598/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!